JP2014503537A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503537A5
JP2014503537A5 JP2013545218A JP2013545218A JP2014503537A5 JP 2014503537 A5 JP2014503537 A5 JP 2014503537A5 JP 2013545218 A JP2013545218 A JP 2013545218A JP 2013545218 A JP2013545218 A JP 2013545218A JP 2014503537 A5 JP2014503537 A5 JP 2014503537A5
Authority
JP
Japan
Prior art keywords
cancer
breast cancer
positive
treatment
body according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013545218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503537A (ja
JP5886873B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/073041 external-priority patent/WO2012084711A1/en
Publication of JP2014503537A publication Critical patent/JP2014503537A/ja
Publication of JP2014503537A5 publication Critical patent/JP2014503537A5/ja
Application granted granted Critical
Publication of JP5886873B2 publication Critical patent/JP5886873B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013545218A 2010-12-24 2011-12-16 Ｎ置換アゼチジン誘導体 Expired - Fee Related JP5886873B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10196960.8 2010-12-24
EP10196960 2010-12-24
PCT/EP2011/073041 WO2012084711A1 (en) 2010-12-24 2011-12-16 N-substituted azetidine derivatives

Publications (3)

Publication Number Publication Date
JP2014503537A JP2014503537A (ja) 2014-02-13
JP2014503537A5 true JP2014503537A5 (enExample) 2014-08-21
JP5886873B2 JP5886873B2 (ja) 2016-03-16

Family

ID=43778253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013545218A Expired - Fee Related JP5886873B2 (ja) 2010-12-24 2011-12-16 Ｎ置換アゼチジン誘導体

Country Status (7)

Country Link
US (1) US9540361B2 (enExample)
EP (1) EP2655367B1 (enExample)
JP (1) JP5886873B2 (enExample)
AU (1) AU2011347718B2 (enExample)
CA (1) CA2819299A1 (enExample)
ES (1) ES2586908T3 (enExample)
WO (1) WO2012084711A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
HUE039052T2 (hu) 2013-02-19 2018-12-28 Novartis Ag Benzotiofénszármazékok és azok készítményei szelektív ösztrogén receptor lebontóként
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
WO2016174551A1 (en) * 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
CN108349952A (zh) * 2015-11-09 2018-07-31 豪夫迈·罗氏有限公司 四氢萘雌激素受体调节剂及其用途
ES2935125T3 (es) 2015-12-09 2023-03-01 Univ Illinois Reguladores a la baja selectivos de los receptores de estrógenos con base en benzotiofeno
AU2017221083B2 (en) * 2016-02-15 2021-06-24 Sanofi 6,7-dihydro-5H-benzo[7]annulene derivatives as estrogen receptor modulators
US9969732B2 (en) * 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
BR112018077136A2 (pt) 2016-07-01 2019-04-30 G1 Therapeutics, Inc. composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis.
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
JOP20190090B1 (ar) * 2016-10-24 2023-03-28 Astrazeneca Ab مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
SG11201903908PA (en) 2016-11-17 2019-05-30 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
AR110728A1 (es) 2017-01-06 2019-04-24 G1 Therapeutics Inc Terapia combinada para el tratamiento del cáncer
WO2018138739A1 (en) 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
TW201835064A (zh) 2017-02-10 2018-10-01 美商G1治療公司 苯并噻吩雌激素受體調節劑
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
EP3641762B1 (en) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CA3067873A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of g1t38 and methods of manufacture thereof
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
WO2019157020A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
TWI915239B (zh) 2018-06-21 2026-02-11 瑞士商赫孚孟拉羅股份公司 3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法
ES2923412T3 (es) 2018-09-07 2022-09-27 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
JP7680438B2 (ja) 2019-10-01 2025-05-20 サノフイ 新規の置換６，７－ジヒドロ－５ｈ－ベンゾ［７］アンヌレン化合物、その製造方法およびその治療的使用
BR112022009705A2 (pt) 2019-12-09 2022-08-09 Sanofi Sa Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica
EP4681715A3 (en) 2019-12-20 2026-01-28 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
IL295709A (en) 2020-03-05 2022-10-01 C4 Therapeutics Inc Compounds for targeted degradation of brd9
MX2022010425A (es) 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
EP4192458A4 (en) 2020-08-05 2024-09-04 C4 Therapeutics, Inc. COMPOUNDS FOR TARGETED DEGRADATION OF RET
US12595230B2 (en) 2020-10-19 2026-04-07 Sanofi Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
AU2021366223A1 (en) 2020-10-19 2023-06-22 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
CN113248455A (zh) * 2021-05-25 2021-08-13 湖北科技学院 一种3,5-二取代异噁唑类衍生物及其合成方法
JP2024523839A (ja) 2021-06-08 2024-07-02 シーフォー セラピューティクス， インコーポレイテッド 突然変異体ｂｒａｆを分解する療法薬
WO2023059714A1 (en) * 2021-10-06 2023-04-13 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
KR20250055538A (ko) 2022-08-03 2025-04-24 브리스톨-마이어스 스큅 컴퍼니 Ret 단백질을 조정하기 위한 화합물
CN117924262A (zh) * 2022-10-14 2024-04-26 中国科学院上海药物研究所 二氢苯并噻喃类衍生物及其制备方法和用途
JP2025540906A (ja) 2022-11-04 2025-12-17 ブリストル－マイヤーズ スクイブ カンパニー Ｒｅｔ－ｌｄｄタンパク質阻害剤
CN120569388A (zh) 2022-11-04 2025-08-29 百时美施贵宝公司 Ret-ldd蛋白降解剂
CN116813603B (zh) * 2023-06-02 2024-10-22 成都市第三人民医院 一种选择性雌激素受体α降解化合物及其制备方法和应用
AU2024310341A1 (en) 2023-06-30 2026-02-12 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983245A (en) * 1975-02-06 1976-09-28 Smithkline Corporation Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
TW200304371A (en) * 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
US20030225132A1 (en) 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
SI1501819T1 (sl) 2002-04-24 2011-01-31 Merck Sharp & Dohme Modulatorji estrogen receptorjev
CA2512000C (en) * 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
AU2008326381B2 (en) * 2007-11-21 2014-10-23 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammation

Similar Documents

Publication Publication Date Title
GT201500206A (es) Modulador del receptor de andrógeno y usos de este
IL208844A0 (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer, etc
MX2015011579A (es) Terapia de combinacion para el tratamiento de la neoplasia.
MX2010005221A (es) Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
IL252766A0 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
SG11201603462SA (en) Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction
IL247093A0 (en) Progesterone antagonists such as 4124–cdb in the treatment of breast cancer
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
HK1221424A1 (zh) 治疗癌症的药物组合
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
MX368234B (es) Conjugados de anticuerpo-fármaco (adcs) que contienen duocarmicina para usarse en el tratamiento de cáncer endometrial.
PH12013501127A1 (en) Use of sigma ligands in bone cancer pain
NI201200071A (es) Nuevo uso antitumoral de cabazitaxel
PH12016501550B1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
LT3324994T (lt) Nx-1207, skirtas panaudoti chirurgijos poreikio sumažinimo metode pacientams, sergantiems gerybine prostatos hiperplazija
NZ626736A (en) Phragamalin limonoids for the treatment of sexual dysfunction
MX2015016550A (es) Antagonistas de imidazolil progesterona.
CL2011002774A1 (es) Combinacion farmaceutica que comprende cabazitaxel y capecitabina, en forma de base, sal, hidrato o solvato; uso para el tratamiento del cancer de mama metastasico.
PH12012501812A1 (en) Compositions and methods for non-toxic delivery of antiprogestins
LT2012006A (lt) 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui
IN2012DE00138A (enExample)
Boisen et al. Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges
NZ742470A (en) Combination therapy for cancer